The
organs-on-chips market is expected to reach USD 45.6 million by 2022 from USD 9.6
million in 2017, at a CAGR of 36.6%. The growth
of this market is mainly driven by factors such as growing focus on
developing alternatives for animal testing models, significant increase in
research funding and venture capital investments for the development of
organs-on-chips, technological advancements and products launches, growing
number of partnerships and collaborations between pharmaceutical companies and
organs-on-chips manufacturers, and growing need for early detection of drug
toxicity to minimize financial losses due to late stage drug failure.
Browse
68 market data Tables and 27 Figures spread through 117 Pages and in-depth
TOC on "Organs-on-chips
Market".
Agreements,
collaborations, and partnerships accounted for the largest share of the overall
growth strategies followed by key players between 2014 and 2017. Some of the companies that adopted this strategy are CN Bio
(UK),
Emulate (US), TissUse (Germany), Mimetas
(Netherland), and InSphero (Switzerland).
The
organs-on-chips market is emerging and competitive in nature, with a number of
small players competing for market space (including startups firms). Prominent
players in this market include Mimetas (Netherlands), Emulate (US), InSphero
(Switzerland), Ascendance Bio (US), CN Bio (UK), TissUse (Germany), Kirkstall
(UK), HUREL (HUREL) (US), SynVivo (US), AxoSim (US), and Nortis (US).
CN
Bio held the leading position in the global organs-on-chips market in 2016. The
company offers its products and services for drug discovery and drug safety
programs. To enhance its production capabilities and applications, the company
focuses on adopting inorganic strategies such as collaborations and agreements.
Over the last three years, CN Bio has been a part of six such initiatives that
helped the company enhance its presence in this market. For instance, in 2017,
CN Bio collaborated with AstraZeneca (UK) to validate a new in vitro tool to
predict optimized drug dosing regimens for multi-drug therapies. Furthermore,
in 2015, CN Bio collaborated with Alnylam Pharmaceuticals (US) to test and
develop therapeutics for liver diseases and infections by using LiverChip, CN
Bio’s human liver-on-a-chip platform.
Download PDF Brochure @
Emulate
is one of the key players in the organs-on-chips market. The company offers
organs-on-chips primarily through collaborations with various industry players.
For instance, in 2016, Emulate collaborated with LabCorp (US) to incorporate
Emulate’s organs-on-chips technology into pre-clinical drug evaluation and
testing services. Furthermore, in 2016, Emulate collaborated with Seres
Therapeutics (US) to develop an advanced version of Emulate’s Intestine-Chip
platform. Such developments enabled the company to expand its presence in the
market.
No comments:
Post a Comment